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Calcineurin, a Ca2calmodulin-dependent protein phosphatase, is
the common target for two immunophilin–immunosuppressant
complexes, cyclophilin A–cyclosporin A (CyPA-CsA) and FKBP–
FK506. How the two structurally distinct immunophilin–drug com-
plexes bind the same target has remained unknown. We report the
crystal structure of calcineurin (CN) in complex with CyPA-CsA at
2.8-Å resolution. The CyPA-CsA complex binds to a composite
surface formed by the catalytic and regulatory subunits of CN,
where the complex of FK506 and its binding protein FKBP also
binds. While the majority of the CN residues involved in the binding
are common for both immunophilin-immunosuppressant com-
plexes, a significant number of the residues are distinct. Unlike
FKBP-FK506, CyPA-CsA interacts with Arg-122 at the active site of
CN, implying direct involvement of CyPA-CsA in the regulation of
CN catalysis. The simultaneous interaction of CyPA with both the
composite surface and the active site of CN suggests that the
composite surface may serve as a substrate recognition site re-
sponsible for the narrow substrate specificity of CN. The compar-
ison of CyPA-CsA-CN with FKBP-FK506-CN significantly contributes
to understanding the molecular basis of regulation of CN activity
by the immunophilin–immunosuppressant.
immunosuppressants  FK506  FK506-binding protein 
protein phosphatase  T cell
Calcineurin (CN) is a unique serinethreonine protein phos-phatase (PP3 or PP2B) in its regulation by the second
messenger Ca2 and calmodulin. CN is involved in many bio-
logical processes, including immune responses (1–5), the second
messenger cAMP pathway (3, 6), NaK ion transportation in
the nephron (7), cell cycle progression in lower eukaryotes (8),
cardiac hypertrophy (9), and memory formation (10, 11). The
most extensively studied function of CN is its role in the signal
transduction pathway during T cell activation. CN has been
shown to be a common receptor for two immunophilin–
immunosuppressant complexes, cyclophilin A-cyclosporin A
(CyPA-CsA) and FK506-binding protein (FKBP)-FK506 (12,
13). The binding of CyPA-CsA or FKBP-FK506 inhibits the
calcium-dependent dephosphorylation of the transcription fac-
tor nuclear factor of activated T cell (NFAT) by CN, thus
blocking T cell receptor-mediated cytokine transcription and
T-cell activation (14, 15).
Since the discovery of CN as a common target for both
CyPA-CsA and FKBP-FK506 complexes, how two structurally
distinct immunophilin–immunosuppressant complexes recog-
nize a common target has remained a mystery. While the crystal
structures of CN and its complex with FKBP-FK506 have shed
light on the molecular recognition of CN by FKBP-FK506 (16,
17), the CyPA-CsA-CN structure has remained elusive. We
report here the crystal structure of CyPA-CsA-CN at 2.8-Å
resolution. The structure revealed that CyPA-CsA and FKBP-
FK506 are bound to the same surface of CN, thus providing a
molecular basis for understanding the regulation of CN activity
by the immunophilin–immunosuppressant.
Methods
Protein Purification. The catalytic subunit (CNA, 61 kDa) and
regulatory subunit (CNB, 19 kDa) of the  isoform of human
CN were coexpressed in Escherichia coli and purified by using
a previously described procedure with slight modifications
(18). The recombinant human CyPA was expressed as a
glutathione S-transferase (GST) fusion protein in E. coli BL21
and purified by glutathione-agarose beads (Sigma). The CyPA-
CsA-CN complex was prepared by a four-step procedure:
(i) purification of recombinant human CN by Ni NTA (Qiagen,
Valencia, CA) and Q-Sepharose (Pharmacia) columns,
(ii) purification of GST-CyPA by glutathione beads, (iii) incu-
bation of CN with GST-CyPA in the presence of CsA and
cleavage of the CyPA-CsA-CN complex from GST by throm-
bin, and (iv) further purification of the CyPA-CsA-CN com-
plex by a Superdex 200 gel filtration column (Pharmacia). This
procedure produced a truncated CNA subunit with an appar-
ent molecular mass of 43 kDa.
Crystallization and Data Collection. Two crystal forms were ob-
tained by vapor diffusion, using the CyPA-CsA-CN complex at
a concentration of about 15 mgml in a storage buffer consisting
of 0.1 M NaCl, 20 mM TrisHCl (pH 7.5), 1 mM 2-mercapto-
ethanol, and 2 mM CaCl2. The trigonal crystals were grown
against a well buffer of 0.1 M Hepes (pH 7.5) and 1.5 M Li2SO4,
and they are in the space group P3221 with cell dimensions of
a  b  135.0 and c  121.0 Å. A diffraction data set of the
trigonal crystal was collected on beamline X12C at Brookhaven
National Laboratory and has Rmerge of 0.088 and completeness
of 87.9% to 2.8-Å resolution.
The tetragonal crystals of CyPA-CsA-CN were grown by
hanging drop against a well buffer containing 0.1 M sodium
cacodylate (pH 6.5), 0.2 M MgCl2, 13% PEG 8000, and 2.5%
ethanol. The protein drop was made up of protein and well
buffer in a 2:1 ratio. The CyPA-CsA-CN crystals are in the
space group P41212 with cell dimensions of a  b  108.7 and
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c  316.6 Å. The diffraction data of the tetragonal CyPA-
CsA-CN crystal were collected on beamline BioCars 14C of
the Advanced Photon Source at Argonne National Laboratory
at 100 K and were processed with the HKL software (Table 1).
Structure Determination. The crystal in the space group P3221
contains one complex of CyPA-CsA-CN in the crystallographic
asymmetric unit. The CyPA-CsA-CN structure in P3221 was
solved by molecular replacement program AMORE using indi-
vidual subunits of CyPA (19) and CNA and CNB from the
structure of FKBP-FK506-CN (16, 17). The orientation of CNA
was first located, yielding a correlation coefficient of 0.37 and R
factor of 0.39 for the data between 4- and 8-Å resolution. When
CyPA was added, the correlation coefficient and R factor were
improved to 0.52 and 0.35, respectively. However, the location
for CNB was ambiguous in the rotation and translation search.
The orientation of CNB was determined by superposition of the
CNA subunit over the CN-FKBP structure. CsA was built into
the electron density map that was calculated from the model of
CyPA-CN without CsA. The structure of CyPA-CsA-CN in
P3221 was refined by X-PLOR to R factor of 0.23 and Rfree of 0.36
for 13,586 reflections between 20.0- and 3.5-Å resolution.
The refined structure of the CyPA-CsA-CN complex in P3221
was then used to solve the structure in the space group P41212.
Two solutions from the rotation and translation search were
easily recognized and corresponded to two molecules in the
crystallographic asymmetric unit. The translational search using
two molecules of CyPA-CsA-CN yielded an R factor of 0.44 and
correlation coefficient of 0.45 for 14,453 reflections between 8-
and 4-Å resolution. The orientations of individual subunits of
CyPA, CNA, and CNB were optimized by rigid-body refinement
of CNS (20). The atomic model was rebuilt by using the program
O (21) and refined by CNS (Table 1).
Results and Discussion
Architecture of the CyPA-CsA-CN Structure. The current CyPA-
CsA-CN structure includes full-length CyPA (residues 1–165),
CsA (11 residues), truncated CNA (residues 1–372), and CNB
residues 10–169. The electron density was excellent for CNA,
CyPA, and CsA, as shown in an example of the electron density
of CsA (Fig. 1). The N-terminal residues 1–13 of one of two
CNAs in the crystallographic asymmetric unit can be traced in
the electron density without difficulty. The electron density for
the N-terminal domain of CNB (residues 10–85) is relatively
weak, but the secondary structure elements and two calcium sites
in the domain are clearly visible in the map calculated from the
CyPA-CsA-CN structure omitting the domain. The CNB subunit
has average B factors of 96.6 Å2 for the N-terminal domains and
74.1 Å2 for the C-terminal domains (residues 86–169), in com-
parison to the average of 64.3 Å2 for all atoms in the entire
structure (Table 1). The relatively large B factor and the weak
electron density for the N-terminal domain of CNB likely reflect
the conformational f lexibility of this region. We speculate that
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Bond length, Å 0.013
Angle, ° 1.67









*The numbers in parentheses are the statistics for the 2.8- to 2.9-Å resolution
shell.
Fig. 1. Stereoview of electron density for CsA. The (2Fo  Fc) map was calculated from the structure-omitted CsA and contoured at 1.5.
12038  www.pnas.orgcgidoi10.1073pnas.192206699 Huai et al.
this conformational f lexibility may play a role in the regulation
of the CN phosphatase activity by CNB and calcium.
The truncated CNA subunit (residues 1–372) contains a
catalytic domain and the CNB-binding helix (BBH) (Fig. 2). The
catalytic domain consists of a central -sheet flanked by -he-
lices and has folding similar to other serinethreonine protein
phosphatases such as PP1 and PP2A (22). The active site metal
ions were assumed as Fe3 and Zn2 without further verification
because of the resolution limit. The N-terminal residues 1–13 of
one CNA in the crystallographic asymmetric unit interact with
the active site residues of the second CNA by crystallographic
symmetry. These interactions are likely the consequence of the
crystal packing without biological relevance. The BBH of CNA
embeds in CNB and forms a composite surface together with
CNB for binding of CyPA-CsA as well as FKBP-FK506. CNB
comprises two domains, each of which has two calcium-binding
sites with a folding pattern similar to calmodulin. CyPA in the
CyPA-CsA-CN complex is an eight-stranded -barrel with the
same folding as the unligated CyPA (Fig. 2).
Subtle Conformational Changes of CN upon CyPA-CsA Binding. The
conformations of CyPA, CsA, CNA, and CNB in the CyPA-
CsA-CN complex are similar to the corresponding subunits in
the CyPA-CsA binary complex (19, 23), unbound CN (17), and
the FKBP-FK506-CN complex (16, 17). Superposition of the C
atoms of the corresponding subunits revealed average displace-
ments of 0.39 Å for CyPA between the binary CyPA-CsA and
tertiary CyPA-CsA-CN complexes, and 0.66 and 0.79 Å for CNA
and CNB between CyPA-CsA-CN and unligated CN, indicating
no substantial change of overall molecular conformations upon
formation of the CyPA-CsA-CN complex. In contrast, significant
local migration was observed for BBH of CNA (Fig. 3). The
averaged displacement for the C atoms of residues 354–372 of
CNA between the unbound CN and CyPA-CsA-CN structures
was 2.64 Å, about 4 times the overall average of 0.66 Å. The
corresponding residues in FKBP-FK506-CN also showed signif-
icant migration of the C atoms of the same domain with an
average displacement 1.60 Å, more than 3 times the overall
average 0.49 Å upon FKBP-FK506 binding. Thus, the movement
of BBH appears as a consequence of binding of CN to either
immunophilin–drug complex.
The Common and Distinct Recognition Elements in CN for CyPA-CsA
and FKBP-FK506. A comparison of CyPA-CsA-CN with FKBP-
FK506-CN revealed that both CyPA-CsA and FKBP-FK506 bind
to the same region of CN and share major common recognition
elements on CN (Fig. 4). Trp-352 of CNA is a key residue
commonly recognized by both immunosuppressive drugs, as its
N2 forms a hydrogen bond with the backbone carbonyl oxygen
of Val-5 of CsA in CyPA-CsA-CN or with O7 and O8 of FK506
in FKBP-FK506-CN. In addition, Trp-352 and Phe-356 of CNA
and Met-118 and Val-119 of CNB make multiple hydrophobic
contacts with residues 2–6 of CsA or a group of atoms of FK506
(Fig. 4). At the protein level, O1 of Glu-47, N2 of Gln-50, and
N2 of Asn-122 of CNB form hydrogen bonds with O of Gly-80,
O2 of Glu-81, and O of Ala-103 of CyPA, respectively. These
three residues also form hydrogen bonds with Gln-53, Glu-54,
and Lys-47 of FKBP. For the common van der Waals interac-
tions, residues Tyr-159, Phe-160, Leu-312, Val-314, Asn-345, and
Pro-355 in CNA make contact with Pro-50, Arg-148, Ser-147,
Trp-121, Asn-149, and Thr-73 of CyPA, or Asp-32, Lys-34,
Lys-35, Gly-89, and Pro-88 of FKBP (16, 17).
On the other hand, a significant number of CN residues
interacting with CyPA-CsA differ from those with FKBP-FK506.
First, the majority of the hydrogen bonds between CN and
CyPA-CsA are different from those between CN and FKBP-
FK506. Thus, five hydrogen bonds were uniquely observed
between CN and CyPA-CsA: Arg-122 (CNA)Arg-148 (CyPA),
Tyr-341 (CNA)Ala-7 (CsA), Glu-359 (CNA)Arg-69 (CyPA),
Gln-50 (CNB)Lys-82 (CyPA), and Lys-164 (CNB)Asn-71
(CyPA) (Fig. 4 A and C). In comparison, four hydrogen bonds
Fig. 2. Ribbon representation of CyPA-CsA-CN. Color codes are CNA, gold;
CNB, cyan; CsA, green; CyPA, red; Zn2 and Fe3, pink; and calcium, blue. The
residues from CN involved in binding of CyPA-CsA are shown as blue balls.
Fig. 3. Stereoview of the superposition of C atoms of CyPA-CsA-CN (red) over unligated CNA (green) and FKBP-FK506-CN (yellow). The complex structures were
overlaid with optimal overlap of the catalytic domain of CNA.








are unique for CN and FKBP-FK506: Tyr-159 (CNA)Asp-32
(FKBP), Leu-312 (CNA)Lys-35 (FKBP), Asn-121
(CNB)Lys-44 (FKBP), and Gln-127 (CNB)Arg-42 (FKBP)
(16, 17). Particularly interesting is the hydrogen bond between
Arg-148 of CyPA and the active site residue Arg-122 of CAN,
which may force the reorientation of the side chain of Arg-122,
thus directly affecting the catalytic activity of CN. In contrast, the
nearest residue from FKBP, Lys-34, is situated more than 5 Å
away from Arg-122, too far to exert the same effect as Arg-148
of CyPA. This hydrogen bonding difference might imply a
potentially different mechanism on regulation of CN catalysis by
the CyPA-CsA complex. In addition, a group of residues from
CN involved in van der Waals interactions with CyPA-CsA are
distinct from those interacting with FKBP-FK506. Thus, Arg-
122, Tyr-315, Trp-342, and Thr-362 of CNA, and Lys-164 of CNB
take part in van der Waals interactions only with CyPA-CsA,
whereas Asp-313, Met-347, and Thr-351 of CNA and Asn-121
and Gln-127 of CNB uniquely contact FKBP-FK506 (Fig. 4).
In summary, among the 25 residues of CN involved in hydro-
gen bonds or hydrophobic interactions with CyPA-CsA, 20
residues are common to those of FKBP-FK506, 5 (Arg-122,
Tyr-315, Trp-342, and Thr-362 of CNA and Lys-164 of CNB)
uniquely interact with CyPA-CsA. Similarly, 5 residues of Asp-
313, Met-347, and Thr-351 of CNA and Asn-121 and Gln-127 of
CNB come in contact only with FKBP-FK506. Although the
majority of the CN residues are common for binding of the two
structurally distinct immunophilin–drug complexes, the patterns
of recognition are dramatically different. For example, Tyr-341
forms a hydrogen bond with CsA, but takes part in a van der
Waals interaction with Arg-42 of FKBP. Another interesting
feature is lower degree of conservation of hydrogen bonds. Of
the nine hydrogen bonds between CyPA-CsA and CN, only four
are common to FKBP-FK506. This character of recognition
diversity of the composite surface may imply its capacity for
binding of a variety of protein substrates.
The common and distinct interactions of CN with the two
immunophilin–drug complexes correlate with the properties of
many, but not all, known CN mutants. The unique hydrogen
bond between Tyr-341 of CNA and CsA can account for the
observation that mutation of Tyr-341 to Phe rendered T lym-
phocytes and yeast resistant to CsA, but not to FK506 (24, 25).
Similarly, mutation of Thr-350 of yeast CN CMP-1 to either Lys
or Arg, which corresponds to Val-314 in human CNA, leads to
selective resistance to CsA. The resistance to CsA may be
explained by the disruption of the van der Waals contact
between Val-314 of CNA and Trp-121 of CyPA upon introduc-
tion of positively charged Lys or Arg. However, it is less apparent
why the same mutant remained sensitive to FK506, as Val-314
also interacts with Lys-35 of FKBP. Trp-352 is another residue
whose mutant phenotype is not obvious from the structure. The
W352C equivalent mutant of yeast CMP-1 exhibited FK506
resistance, but no change in sensitivity to CsA (25). As Trp-352
has hydrophobic contacts and forms a hydrogen bond with both
CsA and FK506 (Fig. 4), one would have predicted that its
mutation to Cys should lead to a decrease in binding of CyPA-
CsA as well as FKBP-FK506. One possible explanation for the
selective resistance of the W352C mutant to FK506 is that
Trp-352 is the only residue forming a hydrogen bond with FK506,
and thus removal of the Trp-352 side chain causes a net loss of
binding energy between FKBP-FK506 and CN. In contrast, CsA
has two hydrogen bonds with Tyr-341 and Trp-352, and thus loss
of contacts with Trp-352 upon its mutation may be compensated
by the interactions with Tyr-341. In addition to the drug-resistant
mutants isolated from the yeast genetic screen, mutagenesis of
Val-119 and Leu-123 of CNB or both together significantly
decreases the affinity for CyPA-CsA (26). This can be explained
by the contacts of both residues with CsA. The CNB mutant of
Cryptococcus neoformans with an insertion of two amino acids
between Asn-121 and Gln-127 has reduced binding affinity for
FKBP-FK506 both in vivo and in vitro (27). The crystal structures
show that the loop 121–127 forms three hydrogen bonds and
numerous van der Waals contacts with FKBP and FK506. As a
result, the two-residue insertion will dramatically perturb the
FKBP binding. In contrast, CyPA-CsA has only minor interac-
tions with the loop so that its binding is not substantially affected
by the mutation.
Subtle Conformational Changes of CsA upon Complex Formation and
Their Pharmacological Implications. The conformation of the CsA
backbone and the side chains interacting with CyPA in the ternary
complex of CyPA-CsA-CN are very similar to those in the binary
CyPA-CsA complex (Fig. 5). In addition, four pairs of hydrogen
bonds between CsA and CyPA: MeBmt-1Gln-63, Abu-2Asn-
102, MeLeu-9Trp-121, and MeLeu-10Arg-55, are conserved in
both binary CyPA-CsA (19) and ternary CyPA-CsA-CN com-
plexes. However, the side chains of CN-binding moiety of CsA
Fig. 4. Interfacial interactions between CN and immunophilins–immunosuppressants. CNA and CNB are shown as yellow and cyan ribbons. (A) The CN composite
surface for CyPA-CsA binding. A total of 25 residues of CN are involved in interaction with CyPA-CsA: Arg-122, Tyr-159, Phe-160, Leu-312, Val-314, Tyr-315, Tyr-341,
Trp-342, Pro-344, Asn-345, Trp-352, Ser-353, Pro-355, Phe-356, and Glu-359 of CNA, and Glu-47, Gln-50, Met-118, Val-119, Asn-122, Leu-123, Lys-124, and Lys-164
of CNB. Red balls represent residues interacting with CyPA and green balls represent residues interacting with CsA (green sticks). The residues from CNB are
marked with the letter ‘‘B’’ attached to the residue number. (B) The CN surface for binding of CyPA-CsA and FKBP12-FK506. CN residues in red interact with both
CyPA-CsA and FKBP12-FK506. Green residues are unique for CyPA-CsA binding and blue residues are unique for FKBP-FK506. CsA and FK506 are shown as green
and blue sticks. (C) CyPA residues for recognition of CN (gold) and CsA (blue). CsA is shown in green sticks.
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undergo significant conformational changes. For example, the
torsion angles of the side chain of MeLeu-4 change from (180°, 60°)
to (60°, 180°) upon ternary complex formation to make hydropho-
bic contacts with CNA and CNB.
The CyPA-CsA-CN structure can help us to understand the
structure–activity relationships of a large number of CsA analogs
that were synthesized in attempts to improve the pharmacolog-
ical properties of CsA over the past few decades. Unique among
them are MeBm2t-CsA and MeAla6-CsA (28–30). MeBm2t-CsA
showed a 100-fold decrease in cyclophilin binding but only 3-fold
decrease in potency for inhibition of CN and T cell activation.
The backbone conformation of MeBm2t-CsA is almost identical
to that of CsA in their binary complexes with CyPA, but the
MeBm2t side chain of MeBm2t-CsA deviates from that of CsA
by up to 1.8 Å (Fig. 5). This subtle conformational change may
be explained by the extra methyl group in the MeBm2t side chain
that takes part in intramolecular interactions with MeLeu-6,
MeLeu-10, and MeVal-11, thus rigidifying the conformation of
MeBm2t-CsA. This rigidification of conformation of MeBm2t-
CsA may disfavor its binding to CyPA, but once MeBm2t-CsA is
bound to CyPA, favor the ternary complex formation with CN.
In contrast to MeBm2t-CsA, MeAla6-CsA, in which Leu-6 is
changed to a methylalanine, has a 2-fold decrease in CyPA
binding activity, but a 25-fold decrease in CN inhibition and
about 250-fold decrease in immunosuppressive activity (28, 30).
Given that the side chain of MeLeu-6 in CsA makes extensive
contacts with Tyr-341, Pro-344, and Trp-352 of CNA and
Leu-123 of CNB, it is expected that removal of the three-carbon
isopropyl group from MeLeu-6 of CsA will result in loss of the
most contacts of this residue with CNA and CNB, thus reducing
affinity for CN.
Among the different positions on CsA, the side chain of D-Ala-8
has been shown to be most tolerant of modifications without
significant loss of immunosuppressive activity. Thus, SDZ IMM125,
the Ala-83 Ser analog of CsA with an additional ethanol unit on
the Ser-8 hydroxyl group, possesses immunosuppressive activity
similar to that of CsA (31). Two related analogs, D-Dap8-CsA and
D-Dab8-CsA, also retained significant activity (29). Interestingly, a
CsA analog, PL-CS with attachment of a photoaffinity probe to the
hydroxyl group of Ser-8, is active as evidenced by its photodepen-
dent irreversible inhibition of T cell activation (32), and apparently
forms a ternary complex with CyPA and CN. Examination of the
CyPA-CsA-CN complex indicated that D-Ala-8 of CsA does not
have direct contacts with either CN or CyPA. An open space was
found around D-Ala-8 of CsA in the ternary complex, consistent
with the tolerance of the side chain for modifications without
significant impact on binding.
Direct Interactions of CyPA-CsA with an Active Site Residue of CN and
Its Mechanistic Implications. On the basis of the structure of
FKBP-FK506-CN, it has been proposed that the inhibition of CN
activity by FKBP-FK506 results from spatial blockage of access
for protein substrates to the active site (16). This idea is strongly
supported by the observation that both FKBP-FK506 and CyPA-
CsA bind to the CNA-CNB composite surface near the active
site of CN. Examination of the CyPA-CsA-CN structure, how-
ever, suggests that modulation of CN activity by the immunophil-
in–drug complexes might be more complicated than the spatial
blockade model. The CyPA-CsA-CN structure revealed the
hydrogen bond and hydrophobic interactions between Arg-148
of CyPA and Arg-122 of CNA. These contacts are likely to place
a conformational constraint on the catalytic residue Arg-122,
thus implying direct involvement of CyPA-CsA in regulation of
CN activity. Whereas CyPA-CsA and FKBP-FK506 were shown
to inhibit the phosphatase activity of CN toward a 19-amino acid
phosphopeptide substrate, they stimulated the phosphatase ac-
tivity of CN toward a small substrate, para-nitrophenyl phos-
phate (PNPP; refs. 12 and 33). These paradoxical observations
can now be rationalized, at least in part, by the conformational
change of Arg-122, which may favor PNPP but disfavor the
peptide substrate for binding and catalysis.
The CNA-CNB Composite Surface May Be a Recognition Site Defining
the Narrow Substrate Specificity of CN. CN has relatively narrow
substrate specificity in comparison with other protein phosphatases.
The molecular basis of the substrate specificity of CN has remained
largely unknown. We have shown that CyPA-CsA and the struc-
turally distinct FKBP-FK506 complex share their binding sites on
the composite surface formed by CNA and CNB. The ability of the
CNA-CNB composite surface to bind two structurally distinct
immunophilin–drug complexes suggests the capacity of the surface
to accommodate different protein–ligand complexes. On the basis
of the observation that CyPA-CsA interacts simultaneously with the
CNA-CNB composite surface and the active site residue, we
speculate that the CNA-CNB composite surface may serve as a
general substrate recognition site, defining substrate specificity of
CN. The nearly orthogonal extension of the composite surface from
one end of the catalytic domain forms an L-shaped clamp, restrict-
ing the binding of phosphoprotein substrates that match the shape
and size. Inherent in this model is the existence of a separate
substrate-binding domain from the active site of CN, as observed in
the case of NFAT (34). This model is also consistent with the fact
that BBH of CN represents a unique C-terminal extension of
the phosphatase catalytic domain of CN among protein serine
threonine phosphatases.
The crystal structure of CyPA-CsA-CN in this paper, together
with the previously determined FKBP-FK506-CN complex, re-
veals how the same composite surface achieves the molecular
recognition of two structurally distinct immunophilin–drug com-
plexes. It is reminiscent of the complex between the human
growth hormone and the homodimer of its receptor, in which
two identical receptor subunits used two largely distinct sets of
residues to bind two different surfaces of the growth hormone
(35). Another example is the Fc fragment of human IgG, where
a single protein surface is capable of binding multiple proteins
or peptides (36). With the structural puzzle of immunophilin–
drug recognition by CN solved, how two unrelated immunosup-
Fig. 5. SuperpositionofCsA inthebinaryCyPA-CsAcomplex (purple),CsA inthe
ternary CyPA-CsA-CN complex (gold), and MeBm2t-CsA in the binary CyPA-
MeBm2tCsA complex (blue). MeBmt, N-methyl-(4R)-4-[(E)-2-butenyl]-4-methyl-L-
threonine; MeBm2t, N-methyl-4-[(E)-2-butenyl]-4,4-dimethyl-L-threonine. Color
codes for atoms: carbons as green balls, oxygen as red, and nitrogen as blue.
Residues of MeLeu-9 to 2-aminobutyrate (Abu)-2 (top) bind CyPA, whereas
MeLeu-4 to Ala-7 bind CN (bottom).








pressive natural products, CsA and FK506, have evolved from
different microorganisms to target the same mammalian protein
phosphatase on the same surface remains a mystery.
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